

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 22, 2019**

**APTEVO THERAPEUTICS INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37746**  
(Commission  
File Number)

**81-1567056**  
(IRS Employer  
Identification No.)

**2401 4th Avenue, Suite 1050**  
**Seattle, Washington**  
(Address of Principal Executive Offices)

**98121**  
(Zip Code)

**Registrant's telephone number, including area code: (206) 838-0500**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, \$0.001 par value</b>	<b>APVO</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

Given the reduction in the clinical trial activity of Aptevo Therapeutics Inc. (the “Company”), on October 22, 2019, Scott Stromatt, M.D. agreed to change his status from an employee to a consultant starting on November 1, 2019 and thus resigned as the Chief Medical Officer and SVP, Clinical Development & Medical Affairs of the Company, effective close of business on October 31, 2019. Dr. Stromatt will consult for the Company for a period of 12 months to provide oversight over the Company’s ongoing clinical trial for APVO436, the Company’s lead ADAPTIR bispecific antibody candidate, and provide assistance with respect to other clinical and medical affairs matters as needed. In exchange for such consulting services, Dr. Stromatt will be entitled to compensation of \$11,000 per month.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 25, 2019

APTEVO THERAPEUTICS INC.

By: /s/ Marvin L. White  
Marvin L. White  
President and Chief Executive Officer